Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Maison Solutions Inc. due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors following its IPO in October 2023 [1] Group 1: IPO Details - Maison Solutions filed a registration statement on Form S-1 on May 22, 2023, which was declared effective on September 29, 2023, after six amendments [2] - The IPO was conducted between October 5, 2023, and October 10, 2023, issuing 2,500,000 common shares at an offering price of $4.00 per share, resulting in approximately $10 million in proceeds for the company before expenses [3] Group 2: Allegations in the Complaint - The filed complaint claims that the Offering Documents were negligently prepared, containing untrue statements or omitting necessary facts, thus failing to comply with regulatory standards [4] - Specific allegations include: (1) engagement with auditors and underwriters with poor track records, (2) the principal vendor being an undisclosed related party, and (3) past legal issues faced by Defendant Xu due to business conduct [4]

Core Insights - Syndax Pharmaceuticals has advanced revumenib into the Phase 1b portion of its Phase 1/2 trial for relapsed or refractory metastatic microsatellite stable colorectal cancer, supported by favorable initial data from the Phase 1a trial [1][2][6] Group 1: Trial Details - The Phase 1/2 trial (NCT05731947) aims to evaluate the safety, tolerability, and anti-tumor activity of revumenib in patients with relapsed or refractory metastatic MSS CRC [2] - The Phase 1a portion enrolled 19 patients with a median of four prior therapies, testing three dose levels: 163 mg, 226 mg, and 276 mg three times a day [2] - Revumenib demonstrated a favorable safety profile with no Grade 3 or greater treatment-related adverse events, and common adverse events included decreased appetite, dysgeusia, nausea, and fatigue [2][6] Group 2: Efficacy Results - Initial efficacy results indicated that at doses believed to achieve full target saturation, 44% of patients had stable disease at 8 weeks, and 33% had stable disease at 16 weeks [2] - One patient experienced prolonged stable disease for 32 weeks, supporting the advancement to Phase 1b with a selected dose of 276 mg TID [2][6] Group 3: Company Overview - Syndax Pharmaceuticals is focused on developing innovative cancer therapies, including revumenib and axatilimab, a monoclonal antibody targeting the CSF-1 receptor [4] - The company is preparing for potential product launches later in the year, emphasizing the role of revumenib in treating R/R metastatic MSS CRC [6] Group 4: Industry Context - Metastatic microsatellite stable colorectal cancer is the second leading cause of cancer death in the U.S., with over 55,000 patients estimated in the relapsed or refractory setting annually [7] - The Wnt/β-catenin signaling pathway is a key driver in CRC tumors, and menin inhibition has shown promise in blocking tumor growth in preclinical models [7]

Exhibit 99.1 Maison Solutions Reports Fiscal 2024 Third Quarter and Nine-Month Financial Results MONTEREY PARK, Calif., March 18, 2024 – Maison Solutions Inc. ("Maison Solutions" or the "Company"), (Nasdaq: MSS), a U.S.-based specialty grocery retailer offering traditional Asian food and merchandise to modern consumers, today announced financial results for the third quarter and first nine months of fiscal 2024 ended January 31, 2024. "We continue to make considerable operational progress through store reno ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-41720 MAISON SOLUTIONS INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-41720 MAISON SOLUTIONS INC. (Exact name of registrant as specified in its charter) | Delaware | 84-2498797 | | --- | --- | | (State ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-41720 MAISON SOLUTIONS INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or org ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 333-272123 Maison Solutions Inc. (Exact name of registrant as specified in its charter) Delaware 84-2498797 (State or other jurisdiction of inc ...